These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30828846)

  • 1. Randomised clinical trial: the DPP-4 inhibitor, vildagliptin, inhibits gastric accommodation and increases glucagon-like peptide-1 plasma levels in healthy volunteers.
    Rotondo A; Masuy I; Verbeure W; Biesiekierski JR; Deloose E; Tack J
    Aliment Pharmacol Ther; 2019 Apr; 49(8):997-1004. PubMed ID: 30828846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.
    Vella A; Bock G; Giesler PD; Burton DB; Serra DB; Saylan ML; Deacon CF; Foley JE; Rizza RA; Camilleri M
    Clin Endocrinol (Oxf); 2008 Nov; 69(5):737-44. PubMed ID: 18331607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.
    Kim TE; Lim KS; Park MK; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Sep; 34(9):1986-98. PubMed ID: 22943970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
    Edgerton DS; Johnson KM; Neal DW; Scott M; Hobbs CH; Zhang X; Duttaroy A; Cherrington AD
    Diabetes; 2009 Jan; 58(1):243-9. PubMed ID: 18840785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.
    El-Ouaghlidi A; Rehring E; Holst JJ; Schweizer A; Foley J; Holmes D; Nauck MA
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4165-71. PubMed ID: 17698900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
    Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
    Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between anagliptin concentration showing over 80% inhibition of plasma dipeptidyl peptidase-4 activity and its protective effect against glucagon-like peptide-1 degradation.
    Furuta S; Goto M; Tamura M; Yamashita S; Nakaya K; Furuta Y
    Drug Res (Stuttg); 2014 Mar; 64(3):130-5. PubMed ID: 23965798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist.
    Nauck MA; Kind J; Köthe LD; Holst JJ; Deacon CF; Broschag M; He YL; Kjems L; Foley J
    Diabetes; 2016 Aug; 65(8):2440-7. PubMed ID: 27207543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4.
    Jessen L; Aulinger BA; Hassel JL; Roy KJ; Smith EP; Greer TM; Woods SC; Seeley RJ; D'Alessio DA
    Endocrinology; 2012 Dec; 153(12):5735-45. PubMed ID: 23033273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
    Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
    Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
    Ahrén B; Schweizer A; Dejager S; Villhauer EB; Dunning BE; Foley JE
    Diabetes Obes Metab; 2011 Sep; 13(9):775-83. PubMed ID: 21507182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion.
    Rotondo A; Janssen P; Mulè F; Tack J
    Int J Obes (Lond); 2013 May; 37(5):693-8. PubMed ID: 22846777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
    Wu T; Little TJ; Bound MJ; Borg M; Zhang X; Deacon CF; Horowitz M; Jones KL; Rayner CK
    Diabetes Care; 2016 Apr; 39(4):511-7. PubMed ID: 26786576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients.
    Boschmann M; Engeli S; Dobberstein K; Budziarek P; Strauss A; Boehnke J; Sweep FC; Luft FC; He Y; Foley JE; Jordan J
    J Clin Endocrinol Metab; 2009 Mar; 94(3):846-52. PubMed ID: 19088168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
    Yamaguchi M; Saji T; Mita S; Kulmatycki K; He YL; Furihata K; Sekiguchi K
    Int J Clin Pharmacol Ther; 2013 Aug; 51(8):641-51. PubMed ID: 23782587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
    Moritoh Y; Takeuchi K; Hazama M
    J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small Intestinal Glucose Delivery Affects the Lowering of Blood Glucose by Acute Vildagliptin in Type 2 Diabetes.
    Wu T; Zhang X; Trahair LG; Bound MJ; Little TJ; Deacon CF; Horowitz M; Jones KL; Rayner CK
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4769-4778. PubMed ID: 27598511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.